Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H22N2O8 |
Molecular Weight | 430.408 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12C[C@@]3([H])[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C(=O)C4=C(O)C=CC=C4[C@H]2O
InChI
InChIKey=JCSGAUKCDAVARS-SOUFLCLCSA-N
InChI=1S/C21H22N2O8/c1-23(2)14-9-6-8-12(16(26)11-7(15(8)25)4-3-5-10(11)24)18(28)21(9,31)19(29)13(17(14)27)20(22)30/h3-5,8-9,14-15,24-25,27-28,31H,6H2,1-2H3,(H2,22,30)/t8-,9-,14-,15+,21-/m0/s1
Molecular Formula | C21H22N2O8 |
Molecular Weight | 430.408 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Demecycline is a tetracycline antibiotic drug. Tetracyclines have a broad spectrum of anti-microbial activity and act by interfering with bacterial protein synthesis. Demecycline is used to treat a wide range of infections caused by bacteria. Some of these infections are: Severe acne; Infections of the brain and liver caused by the bacteria Leptospira; Infection caused by Brucella bacteria (brucellosis); Infections caused by Rickettsiae micro-organisms transmitted by lice, fleas, ticks and mites; Infections of the sex organs and organs associated with urination (genito-urinary infections) such as an infection called chancroid, non-gonococcal urethritis; Rare infections such as Tularaemia and bubonic plague. The following undesirable effects have been reported for demecycline: loss of appetite, nausea, vomiting, diarrhea, inflammation of the tongue, difficulty in swallowing, intestinal inflammation, and inflammatory lesions, rashes, redness of the skin, pigmentation, sensitivity to light, acute kidney failure and others.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.medicines.org.uk/emc/product/499/smpc
For Antibiotic Use: 600mg daily in 2 or 4 divided doses
For the treatment of Chronic Hyponatraemia due to SIADH: Initially: 900mg-1200mg daily in divided doses; Maintenance dose: 600-900mg daily in divided doses.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:18:14 GMT 2023
by
admin
on
Fri Dec 15 16:18:14 GMT 2023
|
Record UNII |
TV240CH11P
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1595
Created by
admin on Fri Dec 15 16:18:14 GMT 2023 , Edited by admin on Fri Dec 15 16:18:14 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID001024794
Created by
admin on Fri Dec 15 16:18:14 GMT 2023 , Edited by admin on Fri Dec 15 16:18:14 GMT 2023
|
PRIMARY | |||
|
987-02-0
Created by
admin on Fri Dec 15 16:18:14 GMT 2023 , Edited by admin on Fri Dec 15 16:18:14 GMT 2023
|
PRIMARY | |||
|
SUB06965MIG
Created by
admin on Fri Dec 15 16:18:14 GMT 2023 , Edited by admin on Fri Dec 15 16:18:14 GMT 2023
|
PRIMARY | |||
|
CHEMBL2106517
Created by
admin on Fri Dec 15 16:18:14 GMT 2023 , Edited by admin on Fri Dec 15 16:18:14 GMT 2023
|
PRIMARY | |||
|
100000083711
Created by
admin on Fri Dec 15 16:18:14 GMT 2023 , Edited by admin on Fri Dec 15 16:18:14 GMT 2023
|
PRIMARY | |||
|
C76237
Created by
admin on Fri Dec 15 16:18:14 GMT 2023 , Edited by admin on Fri Dec 15 16:18:14 GMT 2023
|
PRIMARY | |||
|
TV240CH11P
Created by
admin on Fri Dec 15 16:18:14 GMT 2023 , Edited by admin on Fri Dec 15 16:18:14 GMT 2023
|
PRIMARY | |||
|
1644
Created by
admin on Fri Dec 15 16:18:14 GMT 2023 , Edited by admin on Fri Dec 15 16:18:14 GMT 2023
|
PRIMARY | |||
|
54682469
Created by
admin on Fri Dec 15 16:18:14 GMT 2023 , Edited by admin on Fri Dec 15 16:18:14 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |